Protect women from the consequences of infection

STIs are on the rise and remain a significant public health concern.^1,2

The rates of all STIs continue to increase despite long-standing recommendations for annual screening among women <25 years of age.³

Together CT, GC and TV costed the U.S. healthcare system ~$1.1 billion in 2018.⁴

The sequelae of untreated infections add substantial burden to the healthcare system.³

To protect women against the potentially serious adverse outcomes associated with STIs, you need test results that you can trust.⁵

The BD CTGCTV2 assay is designed to address the 3 most prevalent non-viral STIs in a single test from a variety of sample types, providing the accuracy and the flexibility you need for effective patient management.^4-7

Learn more

CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis.

1. National Overview - Sexually Transmitted Disease Surveillance 2020, CDC. 2022. Accessed 29 Apr 2022.
2. Table 24. Trends in Reported Cases and Rates of Reported Cases for Nationally Notifiable STDs, United States, 2016-2020. Accessed 29 Apr 2022.
3. Van Der Pol B et al. Clin Infect Dis. 2019;68(3):375–81.
4. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022.
5. Workowski KA et al. MMWR Recomm Rep. 2021;70(4):1–187.
6. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
7. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].